Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the
management of acute flare in gout patients who are contraindicated to Non-Steroidal
anti-inflammatory drugs and/or colchicine. The efficacy of ACZ885 will be compared to the
corticosteroid triamcinolone acetonide.